ERBB2 and breast carcinoma: In an extra cohort of metastatic stage IV, Her2 negative breast cancer patients, O'shannessy et al. [16] described that the percentage of FRα positive tumors in early stage disease is retained in late stage metastatic disease, as 36% of samples showed FRα positive expression of whom 86% were TN breast cancers.